Arrowhead Pharmaceuticals To Advance Investigational Plozasiran Into Phase 3 CAPITAN Cardiovascular Outcomes Trial
Portfolio Pulse from Benzinga Newsdesk
Arrowhead Pharmaceuticals is advancing its investigational drug Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial, following positive results from the Phase 2 MUIR study. The CAPITAN trial will focus on patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease. Arrowhead is also considering partnership options for the future development of Zodasiran.
June 25, 2024 | 5:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arrowhead Pharmaceuticals is advancing Plozasiran into Phase 3 CAPITAN trial, focusing on cardiovascular outcomes. This follows positive Phase 2 results and indicates a strategic focus on cardiometabolic development.
The advancement of Plozasiran into Phase 3 trials is a significant milestone for Arrowhead Pharmaceuticals, indicating positive clinical progress and a strategic focus on cardiometabolic conditions. This could boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100